DF-9001 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DF-9001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DF-9001 is under development for the treatment of solid tumor, non-small cell lung cancer, head and neck squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer, esophageal adenocarcinoma, gastric cancer, metastatic renal cell carcinoma, metastatic pancreatic cancer and metastatic colorectal cancer. The drug candidate is tri-specific monoclonal antibody targeting cells expressing Epidermal Growth Factor Receptor (EGFR) being developed based on Tri-specific, NK cell Engager Therapy (TriNKET) platform.
Dragonfly Therapeutics overview
Dragonfly Therapeutics (Dragonfly) is a bio-technology company that discovers, develops and commercializes novel immunotherapies to treat cancer. It is investigating tri-specific, NK (natural killer) cell engager therapies against solid and hematological cancers. The company utilizes its proprietary NK cell based TriNKET platform technology to develop anticancer drugs. It works in partnership with University of Washington, The University of Chicago, Seattle Children’s hospital, Massachusetts Institute of Technology and other companies. Dragonfly is headquartered in Waltham, Massachusetts, the US.
For a complete picture of DF-9001’s drug-specific PTSR and LoA scores, buy the report here.